The cell really does not want to be overstimulated
In the SUSTAIN 6 trial, over 3,297 patients with type 2 diabetes with established chronic kidney disease and/or cardiovascular disease underwent randomization to semaglutide or placebo and were followed for 2 years resulting in a 26% risk reduction in the combined endpoint of rate of cardiovascular disease, nonfatal myocardial infarction, or nonfatal stroke [47]
With proper medical supervision, balanced nutrition, and realistic weight-loss goals, most patients see their hair and confidence return
Lets work together to find the best path forward for you
For beneficiaries enrolled in the Low-Income Subsidy (LIS) program, the LIS cost-sharing subsidies will not apply in the Medicare GLP-1 Bridge
Take Action Today Every day matters: Evidence may be lost over time Statutes of limitations are approaching for some patients Early filing may position you better in the MDL Your health and financial recovery are at stake You have nothing to lose and potentially much to gain by finding out if you have a case